ABSTRACT
ANTECEDENTES: La urticaria solar es una urticaria crónica inducible física clasificada también como fotodermatosis idiopática. El objetivo de este trabajo es definir las características fenotípicas y valorar su incidencia. MATERIAL Y MÉTODO: Estudio multicéntrico retrospectivo en el que recogen datos epidemiológicos, características clínicas, fotobiológicas, analíticas y terapéuticas. RESULTADOS: Se ha incluido a 224 pacientes procedentes de 9 Unidades de Fotobiología. La distribución por sexos correspondió a 141 mujeres y 83 varones con una edad media al diagnóstico de 37,9 ańos (rango 3-73). El 26,7% presentaba antecedentes de atopia, con la rinitis alérgica como la manifestación más frecuente (16,5%). Un 75,9% de los pacientes refería clínica solo en zonas fotoexpuestas. El espectro implicado con más frecuencia fue la luz visible aisladamente (31,7%). En el 21% la urticaria solar solo fue posible desencadenarla con luz natural. El tratamiento más empleado por los expertos fueron los antihistamínicos por vía oral (65,46%) seguido por diferentes modalidades de fototerapia (34%). La resolución completa se observó con mayor frecuencia en urticaria solar desencadenada exclusivamente por luz visible o luz natural, con diferencias estadísticamente significativas (p < 0,05) con respecto a otras longitudes de onda. No se observa un incremento de la incidencia anual. CONCLUSIONES: Presentamos la serie de urticaria solar más larga hasta ahora publicada. Las características epidemiológicas, clínicas y fotobiológicas confirman los datos ya conocidos, aunque en nuestra serie destaca un alto índice de fototest negativos. La reactividad exclusiva a luz visible o luz natural se asocia a mayores probabilidades de resolución. No se observa una tendencia al aumento en la incidencia anual
BACKGROUND: Solar urticaria is a chronic inducible urticaria also classified as an idiopathic dermatosis. The objective of this paper is to define the phenotypic characteristics of solar urticaria and to evaluate its incidence. Material and method. This was a retrospective multicenter study in which data were gathered on the epidemiology and clinical, photobiologic, laboratory, and therapeutic characteristics of solar urticaria. RESULTS: A total of 224 patients (141 women and 83 men) were included from 9 photobiology units. The mean age of the patients was 37.9 years (range, 3-73 years). A history of atopy was detected in 26.7%, and the most common presentation was allergic rhinitis (16.5%). Clinical signs were limited to sun-exposed areas in 75.9% of patients. The light spectrum most commonly implicated was visible light only (31.7%), and in 21% of cases it was only possible to trigger solar urticaria with natural light. The treatments most widely used by photobiology experts were oral antihistamines (65.46%), followed by different forms of phototherapy (34%). Complete resolution was observed most often in patients with solar urticaria triggered exclusively by visible or natural light, with statistically significant differences with respect to other wavelengths (P<.05). No increase in the annual incidence of solar urticaria was observed. CONCLUSIONS: We have presented the largest series of solar urticaria published to date. The epidemiological, clinical, and photobiologic findings confirm previously reported data, although there was a particularly high rate of negative phototests in our series. Reactivity exclusively to visible or natural light was associated with a higher probability of resolution. No increasing trend was observed in the annual incidence
Subject(s)
Humans , Male , Female , Adult , Urticaria/pathology , Skin Diseases/complications , Skin Diseases/epidemiology , Photobiology/methods , Retrospective Studies , ProbabilityABSTRACT
BACKGROUND: Solar urticaria is a chronic inducible urticaria also classified as an idiopathic dermatosis. The objective of this paper is to define the phenotypic characteristics of solar urticaria and to evaluate its incidence. MATERIAL AND METHOD: This was a retrospective multicenter study in which data were gathered on the epidemiology and clinical, photobiologic, laboratory, and therapeutic characteristics of solar urticaria. RESULTS: A total of 224 patients (141 women and 83 men) were included from 9 photobiology units. The mean age of the patients was 37.9 years (range, 3-73 years). A history of atopy was detected in 26.7%, and the most common presentation was allergic rhinitis (16.5%). Clinical signs were limited to sun-exposed areas in 75.9% of patients. The light spectrum most commonly implicated was visible light only (31.7%), and in 21% of cases it was only possible to trigger solar urticaria with natural light. The treatments most widely used by photobiology experts were oral antihistamines (65.46%), followed by different forms of phototherapy (34%). Complete resolution was observed most often in patients with solar urticaria triggered exclusively by visible or natural light, with statistically significant differences with respect to other wavelengths (P<.05). No increase in the annual incidence of solar urticaria was observed. CONCLUSIONS: We have presented the largest series of solar urticaria published to date. The epidemiological, clinical, and photobiologic findings confirm previously reported data, although there was a particularly high rate of negative phototests in our series. Reactivity exclusively to visible or natural light was associated with a higher probability of resolution. No increasing trend was observed in the annual incidence.
Subject(s)
Photosensitivity Disorders/etiology , Sunlight/adverse effects , Urticaria/etiology , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Histamine Antagonists/therapeutic use , Humans , Incidence , Male , Middle Aged , Phenotype , Photosensitivity Disorders/epidemiology , Photosensitivity Disorders/pathology , Photosensitivity Disorders/therapy , Phototherapy , Retrospective Studies , Spain/epidemiology , Urticaria/epidemiology , Urticaria/pathology , Urticaria/therapy , Young AdultABSTRACT
BACKGROUND: Omega-3 fatty acids (O3FA) have been used to treat IgA nephropathy (IgAN) but not cutaneous IgA vasculitis (IgAV). CASE REPORT: A 47-year-old female was referred for cutaneous vasculitis. She had a 24-year history of flares of palpable purpura, arthralgia associated with hematuria, and proteinuria. We diagnosed cutaneous IgAV associated with IgAN. We administered prednisone at doses ranging from 10 to 45 mg/day to control the flares. To reduce prednisone exposure, different therapeutic strategies (colchicine, diphenhydramine, hydroxyzine, azathioprine, benzathine penicillin, and mycophenolate mofetil) were applied without success. After 11 years, therapy with O3FA capsules containing 460 mg eicosapentaenoic acid and 380 mg of docosahexaenoic acid t.i.d. was introduced, allowing the prednisone to be stopped 2 years later. When the dose of O3FA was decreased to 1 capsule on alternate days, the cutaneous flares reappeared, but they were again controlled when the patient took 1 O3FA capsule daily. CONCLUSIONS: O3FA can be useful to control cutaneous IgAV.
ABSTRACT
BACKGROUND: Phototesting is a technique that assesses the skin's sensitivity to UV radiation by determining the smallest dose of radiation capable of inducing erythema (minimal erythema dose [MED]) and anomalous responses to UV-A radiation. No phototesting protocol guidelines have been published to date. METHODOLOGY: This was a multicenter prospective cohort study in which 232 healthy volunteers were recruited at 9 hospitals. Phototests were carried out with solar simulators or fluorescent broadband UV-B lamps. Each individual received a total of 5 or 6 incremental doses of erythemal radiation and 4 doses of UV-A radiation. The results were read at 24hours. RESULTS: At hospitals where solar simulators were used, the mean (SD) MED values were 23 (8), 28 (4), 35 (4), and 51 (6) mJ/cm(2) for skin phototypes i to iv, respectively. At hospitals where broadband UV-B lamps were used, these values were 28 (5), 32 (3), and 34 (5) mJ/cm(2) for phototypes ii to iv, respectively. MED values lower than 7, 19, 27, and 38 mJ/cm(2) obtained with solar simulators were considered to indicate a pathologic response for phototypes I to IV, respectively. MED values lower than 18, 24, and 24mJ/cm(2) obtained with broadband UV-B lamps were considered to indicate a pathologic response for phototypes ii to iv, respectively. No anomalous responses were observed at UV-A radiation doses of up to 20J/cm(2). CONCLUSIONS: Results were homogeneous across centers, making it possible to standardize diagnostic phototesting for the various skin phototypes and establish threshold doses that define anomalous responses to UV radiation.
Subject(s)
Erythema/classification , Erythema/etiology , Skin/radiation effects , Ultraviolet Rays , Adult , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Prospective Studies , Skin Tests , Sunlight , Young AdultABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Pemphigus/diagnosis , Dermatitis Herpetiformis/diagnosis , Sulfones/therapeutic useSubject(s)
Anetoderma/complications , Antibodies, Anticardiolipin/blood , Sjogren's Syndrome/complications , Anetoderma/drug therapy , Anetoderma/immunology , Anetoderma/pathology , Antidepressive Agents/therapeutic use , Bulimia/complications , Bulimia/drug therapy , Carpal Tunnel Syndrome/complications , Carpal Tunnel Syndrome/diagnosis , Colchicine/adverse effects , Colchicine/therapeutic use , Dapsone/therapeutic use , Depressive Disorder/complications , Depressive Disorder/drug therapy , Dermis/pathology , Drug Substitution , Duloxetine Hydrochloride , Elastic Tissue/ultrastructure , Female , Gastrointestinal Diseases/chemically induced , Humans , Sjogren's Syndrome/immunology , Thiophenes/therapeutic use , Young AdultSubject(s)
Antiprotozoal Agents/administration & dosage , Antirheumatic Agents/adverse effects , Cryotherapy , Infliximab/adverse effects , Leishmaniasis, Cutaneous/therapy , Meglumine/administration & dosage , Organometallic Compounds/administration & dosage , Adult , Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/drug therapy , Combined Modality Therapy , Humans , Infliximab/therapeutic use , Injections, Intralesional , Leishmaniasis, Cutaneous/chemically induced , Male , Meglumine AntimoniateABSTRACT
Se describe el caso de una paciente que desarrolló granulomas sarcoideos 11 meses después de haber iniciado interferón α pegilado y ribavirina, como tratamiento de la hepatitis crónica C. Las lesiones se localizaban en relación a 3 cuerpos extraños diferentes: sílice en cicatrices cutáneas antiguas, ácido hialurónico que se había inyectado previamente en la cara, y silicona que se detectó en una adenopatía axilar donde había drenado de un implante mamario previo. La paciente también aquejaba tos seca, fiebre y en la analítica se detectó un incremento de la enzima convertidora de angiotensina y de las enzimas hepáticas. A partir de estos hallazgos se diagnosticó de sarcoidosis sistémica y se suspendió el tratamiento antiviral con posterior normalización de las pruebas hepáticas, desaparición de las lesiones cutáneas y de las adenopatías. Los dermatólogos y cosmetólogos deben ser conscientes del riesgo de aparición de manifestaciones sarcoideas en las áreas donde se han realizado implantes estéticos, en los sujetos que en un futuro requieran tratamiento con interferón (AU)
We report the case of a patient who developed sarcoid granulomas 11 months after starting treatment with pegylated interferon alfa and ribavirin for chronic hepatitis C. The sites of the lesions were related to 3 different foreign bodies: silica in old scars on the skin, hyaluronic acid that had been injected into facial tissues, and silicone in an axillary lymph node draining the area of a breast implant. Systemic sarcoidosis was diagnosed on the basis of a history of dry cough and fever and blood tests that revealed elevated angiotensin converting enzyme and liver enzymes. Interruption of the antiviral therapy led to normalization of liver function tests and disappearance of the skin lesions and lymphadenopathies. Dermatologists and cosmetic surgeons should be aware of the risk of sarcoid lesions related to cosmetic implants in patients who may require treatment with interferon in the future (AU)
Subject(s)
Humans , Sarcoidosis/complications , Granuloma, Foreign-Body/diagnosis , Foreign-Body Reaction/diagnosis , Silicon Dioxide/adverse effects , Hyaluronic Acid/adverse effects , Silicones/adverse effectsABSTRACT
We report the case of a patient who developed sarcoid granulomas 11 months after starting treatment with pegylated interferon alfa and ribavirin for chronic hepatitis C. The sites of the lesions were related to 3 different foreign bodies: silica in old scars on the skin, hyaluronic acid that had been injected into facial tissues, and silicone in an axillary lymph node draining the area of a breast implant. Systemic sarcoidosis was diagnosed on the basis of a history of dry cough and fever and blood tests that revealed elevated angiotensin converting enzyme and liver enzymes. Interruption of the antiviral therapy led to normalization of liver function tests and disappearance of the skin lesions and lymphadenopathies. Dermatologists and cosmetic surgeons should be aware of the risk of sarcoid lesions related to cosmetic implants in patients who may require treatment with interferon in the future.
Subject(s)
Breast Implants/adverse effects , Granuloma, Foreign-Body/chemically induced , Granuloma, Foreign-Body/complications , Hyaluronic Acid/adverse effects , Sarcoidosis/complications , Silicon Dioxide/adverse effects , Silicones/adverse effects , Antiviral Agents/adverse effects , Female , Humans , Interferon-alpha/adverse effects , Middle Aged , Polyethylene Glycols/adverse effects , Recombinant Proteins/adverse effects , Sarcoidosis/chemically inducedSubject(s)
Cryptococcosis/diagnosis , Dermatomycoses/diagnosis , Erythema Nodosum/diagnosis , Fungemia/diagnosis , Opportunistic Infections/diagnosis , Postoperative Complications/diagnosis , Adult , Antifungal Agents/therapeutic use , Cryptococcosis/drug therapy , Cryptococcosis/pathology , Dermatomycoses/drug therapy , Dermatomycoses/pathology , Diagnosis, Differential , Female , Fungemia/drug therapy , Fungemia/microbiology , Glomerulonephritis, IGA/surgery , Humans , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Meningitis, Cryptococcal/cerebrospinal fluid , Meningitis, Cryptococcal/diagnosis , Meningitis, Cryptococcal/drug therapy , Opportunistic Infections/drug therapy , Opportunistic Infections/microbiology , Postoperative Complications/drug therapy , Postoperative Complications/microbiologySubject(s)
Autoantibodies/blood , Autoantigens/immunology , Lichen Planus/immunology , Non-Fibrillar Collagens/immunology , Pemphigoid, Bullous/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoblotting , Lichen Planus/pathology , Middle Aged , Pemphigoid, Bullous/pathology , Collagen Type XVIISubject(s)
Cosmetic Techniques/adverse effects , Mycobacterium Infections, Nontuberculous/microbiology , Nontuberculous Mycobacteria/isolation & purification , Soft Tissue Infections/microbiology , Adult , Anti-Infective Agents/therapeutic use , Drug Therapy, Combination , Female , Humans , Injections, Subcutaneous/adverse effects , Middle Aged , Soft Tissue Infections/pathology , Treatment OutcomeABSTRACT
Cutaneous extramedullary hematopoiesis is a rare manifestation of chronic myeloproliferative processes, mainly chronic idiopathic myelofibrosis. In adults, it manifests as macules, papules, nodules, and ulcers on the trunk. The lesions usually appear soon after diagnosis and the possibility of a relationship between splenectomy and the appearance of extramedullary foci of hematopoiesis is still debated. Diagnosis is based on histopathology showing an infiltrate with different combinations of myeloid and erythroid cell precursors and megakaryocytes. Symptomatic treatment is provided alongside treatment of the underlying disease. We report a new case associated with chronic idiopathic myelofibrosis in which foci of cutaneous extramedullary hematopoiesis were observed 9 years after initial diagnosis. The lesions were progressive and the patient went on to develop acute myeloid leukemia.
Subject(s)
Hematopoiesis, Extramedullary , Primary Myelofibrosis/complications , Skin Physiological Phenomena , Female , Humans , Middle AgedABSTRACT
We report two patients with longstanding multiple sclerosis (MS) who developed vesicles and bullae consistent with the diagnosis of bullous pemphigoid (BP). Both patients showed linear IgG at the dermal-epidermal junction, located on the epidermal side of patients' skin previously treated with 1M NaCl. In the two cases, the ELISA test was positive for the extracellular fragment of BP 180. However, the indirect immunofluorescence test (IIF) was repeatedly negative. Therapy either with prednisone plus dapsone or prednisone alone was initiated and the disease was controlled after 23 and 15 months of therapy, in patients 1 and 2, respectively. However, the first patient had a flare-up 2 months after treatment was stopped. The association of MS and BP has been described previously in 35 cases. We compare our two cases with the 25 patients previously reported in detail in the literature. We emphasize the role of the ELISA test in establishing the diagnosis of BP.